Novavax (NASDAQ:NVAX) Has $4 Target From Oppenheimer.

Novavax, Inc. (NASDAQ:NVAX) Corporate Logo

During 2018 Q3 the big money sentiment decreased to 0.93. That’s change of 1.18, from 2018Q2’s 2.11. 18 investors sold all, 37 reduced holdings as Novavax, Inc. ratio dived. 28 increased stakes while 23 funds bought stakes. Funds hold 152.30 million shares thus 5.09% less from 2018Q2’s 160.47 million shares.

Swiss Bankshares holds 665,750 shs. Baker Bros Advisors Limited Partnership reported 4.72 million shs or 0.06% of all its holdings. Weiss Asset Management Lp reported 0% stake. Profund Advsr Ltd holds 0% of its capital in Novavax, Inc. (NASDAQ:NVAX) for 15,561 shs. Bluecrest Limited reported 57,603 shs. Voya Invest has invested 0% of its capital in Novavax, Inc. (NASDAQ:NVAX). Comerica Bancshares reported 12,920 shs. Amer Group reported 252,905 shs. Rock Springs Cap Mngmt L P accumulated 3.25 million shs or 0.22% of the stock. Da Davidson And invested 0% in Novavax, Inc. (NASDAQ:NVAX). Dekabank Deutsche Girozentrale accumulated 123,100 shs. Pictet Asset Mngmt Limited reported 2.99 million shs stake. Tiaa Cref Inv Ltd Co holds 0% or 849,675 shs. Northern Tru reported 4.58 million shs. Wells Fargo Co Mn reported 205,531 shs.

Novavax, Inc. had 0 sales and 1 buying transaction since July 31, 2018. This’s net activity of $11,446.

What Price Target Has Oppenheimer Given Novavax (NASDAQ:NVAX)

Novavax (NASDAQ:NVAX) coverage has begun by Professional analysts at Oppenheimer. It was set Outperform rating and a $4 target price per share on Tuesday morning. target gives a potential upside of 79.37 % from the company’s previous close.

Novavax, Inc. (NASDAQ:NVAX) Ratings Coverage

In total 3 analysts cover Novavax (NASDAQ:NVAX). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. (NASDAQ:NVAX) has 100% bullish analysts. 3 are the (NASDAQ:NVAX)’s ratings reports on Dec 12, 2018 according to StockzIntelligence Inc. On Monday, November 26 PiperJaffray upgraded Novavax, Inc. (NASDAQ:NVAX) to “Overweight” rating. On Friday, September 21 JP Morgan upgraded Novavax, Inc. (NASDAQ:NVAX) to “Overweight” rating.

Ticker’s shares touched $2.23 during the last trading session after 4.21% change.Novavax, Inc. has 10.37 million shares volume, 51.81% up from normal. NVAX is uptrending and has moved 51.77% since December 12, 2017. NVAX outperformed the S&P 500 by 51.77%.

Novavax, Inc. (NASDAQ:NVAX)’s quarterly earnings will be announced on March, 13., Zacks reports. earnings per share of $-0.12 is 25.00 % up from 2017’s $-0.16 EPS. 0.00 % EPS growth is what Wall Street’s forecasts after $-0.12 reported EPS last quarter.

Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants.The company has $853.76 million market cap. The Company’s lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.Last it reported negative earnings. The firm develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial.

For more Novavax, Inc. (NASDAQ:NVAX) news released briefly go to:,,, or The titles are as follows: “Acorda down 12% on Goldman cut in premarket analyst action – Seeking Alpha” released on December 11, 2018, “Novavax: A Break In The Action – Seeking Alpha” on December 03, 2018, “Benzinga’s Top Upgrades, Downgrades For December 11, 2018 – Benzinga” with a publish date: December 11, 2018, “Why Novavax Is Up 60% in 2018 – Nasdaq” and the last “2 Biotech Stocks Poised for Big Gains in 2019 – The Motley Fool” with publication date: December 03, 2018.

Novavax, Inc. (NASDAQ:NVAX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.